GH SEC-arkivering - Guardant Health, Inc.- Årsrapport, fuldmagtserklæring, prospekt

Grundlæggende statistik

LEI	254900M8C3E5VC8BR186
CIK	1576280

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Guardant Health, Inc.

SEC Filings (Chronological Order)

Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.

May 7, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
May 7, 2026	EX-99.1	Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance First quarter 2026 revenue growth of 48% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.30 to $1.32 billion, r Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance First quarter 2026 revenue growth of 48% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.
May 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2026 GUARDANT HEALTH, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2026 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (
May 7, 2026	EX-10.1	Guardant Health, Inc. 2018 Incentive Award Plan Annual Cash Incentive Program Updated as of March 11, 2026 Exhibit 10.1 Guardant Health, Inc. 2018 Incentive Award Plan Annual Cash Incentive Program Updated as of March 11, 2026 Overview This Annual Cash Incentive Program (the “Bonus Plan”) is adopted under Section 7(a) of the Guardant Health, Inc. (the “Company” or “Guardant Health”) 2018 Incentive Award Plan (the “Plan”) and is intended to recognize, reward and retain Participants (as defined below) wh
May 7, 2026	EX-10.2	GUARDANT HEALTH, INC. ELIGIBLE DIRECTOR COMPENSATION PROGRAM (AS ADOPTED ON APRIL 22, 2026, EFFECTIVE AS OF JUNE 17, 2026) Exhibit 10.2 GUARDANT HEALTH, INC. ELIGIBLE DIRECTOR COMPENSATION PROGRAM (AS ADOPTED ON APRIL 22, 2026, EFFECTIVE AS OF JUNE 17, 2026) Eligible Directors (as defined below) on the board of directors (the “Board”) of Guardant Health, Inc. (the “Company”) shall be eligible to receive compensation as set forth in this Eligible Director Compensation Program (this “Program”). The compensation describe
April 28, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
April 28, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi
April 28, 2026	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
April 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2026 GUARDANT HEALTH, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2026 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization
February 20, 2026	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Guardant Health, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the 2018 Incentive Award Plan Othe
February 20, 2026	S-8	As filed with the Securities and Exchange Commission on February 20, 2026 S-8 As filed with the Securities and Exchange Commission on February 20, 2026 Registration No.
February 19, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 19, 2026 GUARDANT HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 19, 2026 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
February 19, 2026	EX-99.1	Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening Expects full year 2026 total revenue to Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening Expects full year 2026 total revenue to grow in the range of 27% to 30% year -over-year PALO ALTO, Calif.
February 19, 2026	EX-19.1	GUARDANT HEALTH, INC. INSIDER TRADING COMPLIANCE POLICY As in effect April 23, 2025 GUARDANT HEALTH, INC. INSIDER TRADING COMPLIANCE POLICY Exhibit 19.1 GUARDANT HEALTH, INC. INSIDER TRADING COMPLIANCE POLICY As in effect April 23, 2025 CONTENTS I. SUMMARY 2 II. STATEMENT OF POLICIES PROHIBITING INSIDER TRADING 2 III. EXPLANATION OF INSIDER TRADING 3 IV. STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING 6 V. ADDITIONAL RESTRICTIONS AND GUIDANCE 8 VI. RULE 10b5-1 TRADING PLANS AND SECTION 16 9 VII. EXECUTION AND RETURN OF CERTIFICATIO
February 19, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
January 12, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2026 GUARDANT HEALTH, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2026 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
January 12, 2026	EX-99.1	Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results Fourth quarter revenue growth of 39% driven by strong Oncology and Screening volume Exhibit 99.1 Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results Fourth quarter revenue growth of 39% driven by strong Oncology and Screening volume PALO ALTO, Calif. January 11, 2026 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025. Fourth qua
November 7, 2025	EX-4.1	GUARDANT HEALTH, INC. U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee Dated as of November 7, 2025 0% Convertible Senior Notes due 2033 EX-4.1 Exhibit 4.1 GUARDANT HEALTH, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of November 7, 2025 0% Convertible Senior Notes due 2033 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 14 Article 2. The Notes 14 Section 2.01. Form, Datin
November 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2025 GUARDANT HEALTH, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
November 7, 2025	EX-1.1	GUARDANT HEALTH, INC. 3,333,333 Shares of Common Stock, par value $0.00001 per share Underwriting Agreement EX-1.1 Exhibit 1.1 GUARDANT HEALTH, INC. 3,333,333 Shares of Common Stock, par value $0.00001 per share Underwriting Agreement November 4, 2025 Goldman Sachs & Co. LLC Jefferies LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and G
November 7, 2025	EX-99.2	Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering EX-99.2 Exhibit 99.2 Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering PALO ALTO, Calif. November 5, 2025 – Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount of 0% convertible senior notes due 2033 (the “notes”) in a private offe
November 7, 2025	EX-99.1	Guardant Health Announces Pricing of Upsized Public Offering of Common Stock EX-99.1 Exhibit 99.1 Guardant Health Announces Pricing of Upsized Public Offering of Common Stock PALO ALTO, Calif. November 5, 2025 – Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 3,333,333 shares of Guardant Health’s common stock at a public offering price of $90.00 per share
November 6, 2025	424B5	3,333,333 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272121 PROSPECTUS SUPPLEMENT (to Prospectus Dated May 22, 2023) 3,333,333 Shares Common Stock We are offering 3,333,333 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “GH.” The last reported sale price of our common stock on the Nasdaq Global Select Market on No
November 6, 2025	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 Guardant Health, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initi
November 5, 2025	FWP	Guardant Health Announces Pricing of Upsized Public Offering of Common Stock FWP Issuer Free Writing Prospectus dated November 4, 2025 Relating to Preliminary Prospectus Supplement dated November 4, 2025 Filed pursuant to Rule 433 Registration Statement No.
November 4, 2025	FWP	Guardant Health Announces Proposed Public Offering of Common Stock FWP Issuer Free Writing Prospectus dated November 4, 2025 Relating to Preliminary Prospectus Supplement dated November 4, 2025 Filed pursuant to Rule 433 Registration Statement No.
November 4, 2025	424B5	Subject to Completion, dated November 4, 2025 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272121 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to Completion, d
October 29, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
October 29, 2025	EX-99.1	Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $965 to $970 Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31% PALO ALTO, Calif.
October 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2025 GUARDANT HEALTH, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
September 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 24, 2025 GUARDANT HEALT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 24, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organiza
September 17, 2025	144	144 144 0001968281 XXXXXXXX LIVE 0001576280 Guardant Health, Inc. 001-38683 3100 HANOVER STREET PALO ALTO CA 94304 855-698-8887 Tariq Musa Director Common Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262 116 6453.00 124705857 09/17/2025 NASDAQ Common 09/15/2025 Restricted Stock Lapse Guardant Health, Inc. N 116 09/15/2025 Equity Compensation N Musa Tariq 3100 HANOVER STREET PALO ALTO CA 94
September 17, 2025	144	144 144 0001214130 XXXXXXXX LIVE 0001576280 Guardant Health, Inc. 001-38683 3100 HANOVER STREET PALO ALTO CA 94304 855-698-8887 POTTER MYRTLE S Director Common Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262 26 1446.00 124705857 09/17/2025 NASDAQ Common 09/15/2025 Restricted Stock Lapse Guardant Health, Inc. N 26 09/15/2025 Equity Compensation N MYRTLE S POTTER 3100 HANOVER STREET PALO AL
September 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2025 GUARDANT HEALT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organiza
September 15, 2025	EX-99.1	Alex M. Azar II Joins Guardant Health Board of Directors Exhibit 99.1 NEWS RELEASE Alex M. Azar II Joins Guardant Health Board of Directors PALO ALTO, Calif., September 15, 2025 - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had ov
September 12, 2025	144	144 144 0001865525 XXXXXXXX LIVE 0001576280 Guardant Health, Inc. 001-38683 3100 HANOVER STREET PALO ALTO CA 94304 855-698-8887 Hidalgo Medina Manuel Director Common Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262 2165 117251.00 124705857 09/12/2025 NASDAQ Common 07/17/2025 Restricted Stock Lapse Guardant Health, Inc. N 2165 07/17/2025 Equity Compensation Y 09/12/2025 Manuel Hidalgo Medin
September 9, 2025	144	144 144 0001752968 XXXXXXXX LIVE 0001576280 Guardant Health, Inc. 001-38683 3100 HANOVER STREET PALO ALTO CA 94304 855-698-8887 Eltoukhy Helmy Officer Common Stock Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102 300000 17835990.00 124705857 09/09/2025 Nasdaq Common Stock 01/07/2021 Restricted Stock Units Issuer N 286065 01/07/2021 Cash Common Stock 11/19/2021 Open Market Purchase Issue
September 2, 2025	144	144 144 0001770749 XXXXXXXX LIVE 0001576280 Guardant Health, Inc. 001-38683 3100 HANOVER STREET PALO ALTO CA 94304 855-698-8887 Joyce Meghan V. Director Common Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262 100 6584.00 124705857 09/02/2025 NASDAQ Common 06/12/2025 Restricted Stock Lapse GUARDANT HEALTH, INC. N 34 06/12/2025 Equity Compensation Common 07/04/2025 Restricted Stock Lapse GUA
July 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
July 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2025 GUARDANT HEALTH, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
July 30, 2025	EX-99.1	Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $915 to $925 Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $915 to $925 million, representing growth of 24% to 25% PALO ALTO, Calif.
June 20, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
April 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
April 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2025 GUARDANT HEALTH, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization
April 30, 2025	EX-99.1	Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% PALO ALTO, Calif.
April 30, 2025	EX-10.3	Third Amendment to Lease, dated April 3, 2025 by and between Registrant and Metropolitan Life Insurance Company
April 30, 2025	EX-10.2	Second Amendment to Lease, dated March 6, 2019 by and between Registrant and Metropolitan Life Insurance Company signed595pen101sagleases SECOND AMENDMENT TO LEASE This Second Amendment to Lease ("Amendment") is entered into, and dated for reference purposes, as of f\'ll-cc.
April 29, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
April 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
April 29, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi
April 9, 2025	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
February 24, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Guardant Health, Inc.
February 24, 2025	S-8	As filed with the Securities and Exchange Commission on February 24, 2025 As filed with the Securities and Exchange Commission on February 24, 2025 Registration No.
February 20, 2025	EX-10.22	018 Incentive Award Plan Annual Cash Incentive Program Exhibit 10.22 Guardant Health, Inc. 2018 Incentive Award Plan Annual Cash Incentive Program Updated as of January 1, 2025 Overview This Annual Cash Incentive Program (the “Bonus Plan”) is adopted under Section 7(a) of the Guardant Health, Inc. (the “Company” or “Guardant Health”) 2018 Incentive Award Plan (the “Plan”) and is intended to recognize, reward and retain Participants (as defined below)
February 20, 2025	EX-21.1	List of Subsidiaries Exhibit 21.1 Subsidiaries of Guardant Health, Inc. Name Jurisdiction of Incorporation Guardant Health AMEA, Inc. Delaware Guardant Health Pte. Ltd. Singapore Guardant Health Japan Corp. Japan Guardant Holdings (Switzerland) GmbH Switzerland Bellwether Bio, Inc. Washington Morpheus Merger Sub, Inc. Delaware Guardant Health Screening Corp. Delaware Guardant Health International, Inc. Delaware Guarda
February 20, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
February 20, 2025	EX-99.1	Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades Expects Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades Expects full year 2025 total revenue to be in the range of $850 to $860 million PALO ALTO, Calif.
February 20, 2025	EX-19.1	nsider Trading Compliance Policy Exhibit 19.1 GUARDANT HEALTH, INC. INSIDER TRADING COMPLIANCE POLICY As in effect October 23, 2024 CONTENTS I. SUMMARY 2 II. STATEMENT OF POLICIES PROHIBITING INSIDER TRADING 2 III. EXPLANATION OF INSIDER TRADING 3 IV. STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING 5 V. ADDITIONAL RESTRICTIONS AND GUIDANCE 8 VI. RULE 10b5-1 TRADING PLANS AND SECTION 16 9 VII. EXECUTION AND RETURN OF CERTIFICAT
February 20, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
February 14, 2025	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 14, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
February 14, 2025	EX-4.1	Indenture, dated as of February 14, 2025, between Guardant Health, Inc. and U.S. Bank Trust Company, National Association, as Trustee Exhibit 4.1 GUARDANT HEALTH, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of February 14, 2025 1.25% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction. 1 Section 1.01. Definitions. 1 Section 1.02. Other Definitions. 12 Section 1.03. Rules of Construction. 13 Article 2. The Notes. 14 Section 2.01. Form, Dat
February 10, 2025	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Guardant Health, Inc.
February 7, 2025	EX-99.1	Guardant Health Announces Debt Exchange Transactions EX-99.1 Exhibit 99.1 Guardant Health Announces Debt Exchange Transactions PALO ALTO, Calif. February 7, 2025 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its outstanding 0% Convertible Senior Notes due 2027 (the “2027
February 7, 2025	EX-10.1	Form of Exchange Agreement Exhibit 10.1 February 6, 2025 Guardant Health, Inc. 3100 Hanover Street Palo Alto, California 94304 Attention: Chief Financial Officer Re: Exchange and/or Subscription for Guardant Health, Inc. Convertible Senior Notes due 2031 Ladies and Gentlemen: Guardant Health, Inc., a Delaware corporation, (the “Company”), is offering a new series of its Convertible Senior Notes due 2031 (the “New Notes”). T
February 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2025 GUARDANT HEALTH, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
January 13, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
January 13, 2025	EX-99.1	Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results Exhibit 99.1 Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results Full year revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds PALO ALTO, Calif. January 13, 2025 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended Dece
November 13, 2024	SC 13G	GH / Guardant Health, Inc. / CADIAN CAPITAL MANAGEMENT, LP Passive Investment SC 13G 1 formsc13g-guardant.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Guardant Health, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 40131M109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap
November 8, 2024	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Guardant Health, Inc.
November 8, 2024	SC 13G	GH / Guardant Health, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
November 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
November 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
November 6, 2024	EX-99.1	Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 34% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield received favorable Medicare pricing of $920 Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 34% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield received favorable Medicare pricing of $920 PALO ALTO, Calif.
October 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2024 GUARDANT HEALTH, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
October 24, 2024	EX-99.1	Roberto A. Mignone Joins Guardant Health Board of Directors Exhibit 99.1 FOR IMMEDIATE RELEASE Roberto A. Mignone Joins Guardant Health Board of Directors PALO ALTO, Calif.- (October 24, 2024) - Guardant Health, Inc. (Nasdaq: GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment man
October 7, 2024	SC 13G	GH / Guardant Health, Inc. / Deep Track Capital, LP Passive Investment SC 13G 1 deeptrack-gh100224.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Guardant Health Inc. (Name of Issuer) Common Stock, $0.00001 Par Value (Title of Class of Securities) 40131M109 (CUSIP Number) October 2, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
October 7, 2024	SC 13G/A	GH / Guardant Health, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
August 23, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Guardant Health, Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Guardant Health, Inc.
August 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2024 GUARDANT HEALTH, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizatio
August 23, 2024	424B5	Up to $400,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272121 PROSPECTUS SUPPLEMENT (to Prospectus Dated May 22, 2023) Up to $400,000,000 Common Stock We have entered into an open market sale agreementSM (the “Sales Agreement”), dated August 23, 2024, with Jefferies LLC (“Jefferies”), relating to the offer and sale of shares of our common stock, par value $0.00001 per share (our “
August 23, 2024	EX-1.1	by and between the Company and Jefferies LLC, dated August 23, 2024 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM August 23, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Guardant Health, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common st
August 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization
August 7, 2024	EX-10.2	Form of Stock Option Agreement under the 2018 Incentive Award Plan Exhibit 10.2 GUARDANT HEALTH, INC. 2018 INCENTIVE AWARD PLAN GLOBAL STOCK OPTION GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the stock option (the “Option”) described in this Global Stock Option Grant Notice (the “Grant Notice”) subject to the terms and conditions of the 2018 Incentive Award Plan, as may be
August 7, 2024	EX-10.4	Form of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan Exhibit 10.4 Founder PSU Agreement GUARDANT HEALTH, INC. 2018 INCENTIVE AWARD PLAN GLOBAL PERFORMANCE-BASED RESTRICTED STOCK UNIT GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Performance-Based Restricted Stock Units (the “PSUs”) described in this Global Performance-Based Restricted Stock Unit Grant Notic
August 7, 2024	EX-10.5	Form of Stock Option Grant Notice and Restricted Stock Unit Grant Notice under the 2023 Employment Inducement Incentive Award Plan Exhibit 10.5 GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the stock option (the “Option”) described in this Stock Option Grant Notice (the “Grant Notice”) subject to the terms and conditions of the 2023 Employment Inducement In
August 7, 2024	EX-10.1	Amended and Restated Executive Severance Plan Exhibit 10.1 GUARDANT HEALTH, INC. EXECUTIVE SEVERANCE PLAN As amended and restated on April 22, 2024 Guardant Health, Inc., a Delaware corporation, (the “Company”) has adopted this Executive Severance Plan, including the attached Exhibits (the “Plan”), for the benefit of Participants (as defined below) on the terms and conditions hereinafter stated. The Plan, as initially adopted on September 15,
August 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
August 7, 2024	EX-99.1	Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield approved by FDA as primary option for CRC scre Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield approved by FDA as primary option for CRC screening and is commercially available in U.
August 7, 2024	EX-10.3	Form of Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan Exhibit 10.3 Founder RSU Agreement GUARDANT HEALTH, INC. 2018 INCENTIVE AWARD PLAN GLOBAL RESTRICTED STOCK UNIT GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Global Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and cond
July 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2024 GUARDANT HEALTH, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
July 29, 2024	EX-99.1	Guardant Health’s Shield EX-99.1 Exhibit 99.1 NEWS RELEASE Guardant Health’s ShieldTM blood test approved by FDA as a primary screening option, clearing path for Medicare reimbursement and a new era of colorectal cancer screening • Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage • Blood test offers easy, convenient
July 18, 2024	EX-99.1	Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors Exhibit 99.1 FOR IMMEDIATE RELEASE Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors PALO ALTO, Calif.—(July 18, 2024)— Guardant Health, Inc. (Nasdaq: GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Onc
July 18, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
July 5, 2024	SC 13G/A	GH / Guardant Health, Inc. / BAILLIE GIFFORD & CO Passive Investment SC 13G/A 1 Guardant2806024.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Guardant Health, Inc. (Amendment No.1) - (Name of Issuer) Common Stock - (Title of Class of Securities) 40131M109 - (CUSIP Number) 28 June 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
June 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2024 GUARDANT HEALTH, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
May 31, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2024 GUARDANT HEALTH, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
May 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2024 GUARDANT HEALTH, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
May 24, 2024	EX-99.1	FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option Exhibit 99.1 NEWS RELEASE FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option May 23, 2024 • The advisory committee offers valuable non-binding recommendations for the FDA • Blood test offers a convenient non-invasive screening option that overcomes barriers associated with current non-invasive s
May 9, 2024	EX-99.1	Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds PALO ALTO, Calif.
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (
April 25, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi
April 25, 2024	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
April 25, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 12, 2024	SC 13G	GH / Guardant Health, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
March 22, 2024	EX-10.1	Form of Letter Agreement Exhibit 10.1 March 18, 2024 Re: Compensation Arrangement Dear [Helmy / AmirAli]: This letter serves to memorialize your agreement with Guardant Health, Inc. (the “Company”) regarding certain compensation-related matters and amends and restates the prior letter by and between you and the Company, dated May 26, 2020 (the “Prior Letter”). Capitalized terms used but not otherwise defined herein shall
March 22, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization
February 23, 2024	S-8	As filed with the Securities and Exchange Commission on February 23, 2024 As filed with the Securities and Exchange Commission on February 23, 2024 Registration No.
February 23, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Guardant Health, Inc.
February 22, 2024	EX-97.1	Policy for Recovery of Erroneously Awarded Compensation GUARDANT HEALTH, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Guardant Health, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of December 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Policy
February 22, 2024	EX-99.1	Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue to be in the range of $655 to $670 milli Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue to be in the range of $655 to $670 million PALO ALTO, Calif.
February 22, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
February 22, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 22, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
February 22, 2024	EX-21.1	List of Subsidiaries Exhibit 21.1 Subsidiaries of Guardant Health, Inc. Name Jurisdiction of Incorporation Guardant Health AMEA, Inc. Delaware Guardant Health Pte. Ltd. Singapore Guardant Health Japan Corp. Japan Guardant Holdings (Switzerland) GmbH Switzerland Bellwether Bio, Inc. Washington Morpheus Merger Sub, Inc. Delaware Guardant Health Screening Corp. Delaware Guardant Health International, Inc. Delaware Guarda
February 13, 2024	SC 13G/A	GH / Guardant Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Guardant Health Inc Title of Class of Securities: Common Stock CUSIP Number: 40131M109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒
February 9, 2024	SC 13G/A	GH / Guardant Health, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 GUARDANT HEALTH INC COMMON STOCK Cusip #40131M109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #40131M109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,244,420 Item 6: 0 Item 7: 5,317,574 Item 8: 0 Item 9:
February 9, 2024	SC 13G/A	GH / Guardant Health, Inc. / Capital International Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
February 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2024 GUARDANT HEALTH, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
January 29, 2024	SC 13G	GH / Guardant Health, Inc. / BAILLIE GIFFORD & CO Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Guardant Health, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 40131M109 - (CUSIP Number) 29 December 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule
January 25, 2024	SC 13G/A	GH / Guardant Health, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us40131m1099012524.txt us40131m1099012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) GUARDANT HEALTH, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 40131M109 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 GUARDANT HEALTH, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizatio
January 8, 2024	EX-99.1	Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results Full year revenue growth of 25% driven by clinical volume growth of 39% Exhibit 99.1 Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results Full year revenue growth of 25% driven by clinical volume growth of 39% PALO ALTO, Calif. January 8, 2024 - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2023. Full year 2023 prelimin
December 21, 2023	424B5	3,387,446 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272121 PROSPECTUS SUPPLEMENT (to Prospectus Dated May 22, 2023) 3,387,446 Shares of Common Stock We are offering 3,387,446 shares of our common stock, par value $0.00001 per share, at an offering price of $26.77 per share directly to certain investors pursuant to this prospectus supplement, the accompanying prospectus an
December 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2023 GUARDANT HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
December 21, 2023	EX-99.1	Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford Exhibit 99.1 Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford PALO ALTO, Calif. Dec 21, 2023 (BUSINESS WIRE) — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its co
December 21, 2023	EX-10.1	Common Stock Purchase Agreement, dated December 20, 2023, between Guardant Health, Inc. and Baillie Gifford Overseas Limited, acting as agent and representative for and on behalf of the investors set forth therein Exhibit 10.1 GUARDANT HEALTH, INC. COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is entered into as of December 20, 2023, by and between Guardant Health, Inc., a Delaware corporation (“Guardant”), and Baillie Gifford Overseas Limited, acting as agent and representative for and on behalf of the investors set forth in Exhibit A hereto (the “Investors”). WHERE
December 21, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) GUARDANT HEALTH, INC.
December 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 19, 2023 GUARDANT HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 19, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
December 19, 2023	EX-99.1	Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test Exhibit 99.1 Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test PALO ALTO, Calif. Dec 19, 2023 (BUSINESS WIRE) — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to rev
November 15, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
November 15, 2023	EX-99.1	Guardant Health to Appeal Federal District Court Verdict EX-99.1 Exhibit 99.1 PRESS RELEASE Guardant Health to Appeal Federal District Court Verdict PALO ALTO, Calif. - (BUSINESS WIRE) - (November 15, 2023) – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guard
November 6, 2023	EX-99.1	Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance Q3 revenue increased 22% year over year driven by clinical volume growth of 35% Raises 2023 revenue guidance to $553 to 556 million Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance Q3 revenue increased 22% year over year driven by clinical volume growth of 35% Raises 2023 revenue guidance to $553 to 556 million PALO ALTO, Calif.
November 6, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
November 6, 2023	EX-10.2	Form of Stock Option Grant Notice and Restricted Stock Unit Grant Notice under the 2023 Employment Inducement Incentive Award Plan GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the stock option (the “Option”) described in this Stock Option Grant Notice (the “Grant Notice”), subject to the terms and conditions of the 2023 Employment Inducement Incentive Awar
November 6, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
November 6, 2023	EX-10.1	2023 Employment Inducement Award Plan, as approved on August 2, 2023 GUARDANT HEALTH, INC. 2023 Employment Inducement Incentive Award Plan (Effective as of August 2, 2023) 1.Purpose. The Plan’s purpose is to enhance the Company’s ability to attract and retain Eligible Individuals who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Sectio
November 3, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
September 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2023 GUARDANT HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
August 10, 2023	S-8	As filed with the Securities and Exchange Commission on August 10, 2023 S-8 As filed with the Securities and Exchange Commission on August 10, 2023 Registration No.
August 10, 2023	EX-99.1B	Form of Stock Option Grant Notice and Stock Option Agreement under the 2023 Employment Inducement Incentive Award Plan Exhibit 99.1(b) GUARDANT HEALTH, INC. FORM OF STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT UNDER THE 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN [ATTACHED] * * * * * GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the
August 10, 2023	EX-99.1A	2023 Employment Inducement Incentive Award Plan EX-99.1a Exhibit 99.1(a) GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN [ATTACHED] * * * * * GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN 1. Purpose. The Plan’s purpose is to enhance the Company’s ability to attract and retain Eligible Individuals who are expected to make important contributions to the Company by providing these individuals with equi
August 10, 2023	EX-99.1C	Form of Restricted Stock Unit Award Grant Notice under the 2023 Employment Inducement Incentive Award Plan EX-99.1c Exhibit 99.1(c) GUARDANT HEALTH, INC. FORM OF RESTRICTED STOCK UNIT AWARD GRANT NOTICE UNDER THE 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN [ATTACHED] * * * * * GUARDANT HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Guardant Health, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant
August 10, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Guardant Health, Inc.
August 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2023 GUARDANT HEALTH, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization
August 3, 2023	EX-99.1	Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance Q2 revenue increased 26% year over year driven by clinical volume growth of 49% Raises 2023 revenue guidance to $545 to $550 million Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance Q2 revenue increased 26% year over year driven by clinical volume growth of 49% Raises 2023 revenue guidance to $545 to $550 million PALO ALTO, Calif.
August 3, 2023	EX-10.1	Executive Severance Plan Exhibit 10.1 GUARDANT HEALTH, INC. EXECUTIVE SEVERANCE PLAN As amended and restated on May 2, 2023 Guardant Health, Inc., a Delaware corporation, (the “Company”) has adopted this Executive Severance Plan, including the attached Exhibits (the “Plan”), for the benefit of Participants (as defined below) on the terms and conditions hereinafter stated. The Plan, as initially adopted on September 15, 20
August 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2023 GUARDANT HEALTH, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization
August 1, 2023	EX-99.1	Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research EX-99.1 Exhibit 99.1 PRESS RELEASE Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research PALO ALTO, CALIF., August 1, 2023 /BUSINESSWIRE/ – Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, today announced an agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequenci
June 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2023 GUARDANT HEALTH, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
May 25, 2023	EX-1.1	Underwriting Agreement, dated as of May 22, 2023, among Guardant Health, Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and SVB Securities LLC, as representatives of the several underwriters named therein. U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains
May 25, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation) (Commission File
May 24, 2023	424B5	12,500,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272121 PROSPECTUS SUPPLEMENT (to Prospectus Dated May 22, 2023) 12,500,000 Shares Common Stock We are offering 12,500,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “GH.” The last reported sale price of our common stock on the Nasdaq Global Select Market on May 22
May 24, 2023	EX-FILING FEES	Youâve Exceeded the SECâs Traffic Limit EX-FILING FEES Exhibit 107 Ex – Filing Fees Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) GUARDANT HEALTH, INC.
May 22, 2023	424B5	Subject to Completion Preliminary Prospectus Supplement dated May 22, 2023 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272121 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
May 22, 2023	EX-4.2	Form of Indenture. EX-4.2 Exhibit 4.2 GUARDANT HEALTH, INC. INDENTURE Dated as of , 20 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section
May 22, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES 6 d494939dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Ag
May 22, 2023	EX-25.1	Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of U.S. Bank Trust Company, National Association, as trustee under the indenture filed as Exhibit 4.2 above. EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036
May 22, 2023	S-3ASR	Powers of Attorney (incorporated by reference to the signature page hereto). S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 22, 2023 Registration No.
May 9, 2023	EX-99.1	Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield EX-99.1 Exhibit 99.1 Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test Shield™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with other guideline-recommended non-invasive CRC screening modalities PALO ALTO, Calif., May 9, 2023 — Guardant Health,
May 9, 2023	EX-99.1	Guardant Health Reports First Quarter 2023 Financial Results Q1 revenue increased 34% year over year driven by clinical volume growth of 45% Raises 2023 revenue guidance to $535 to $545 million Guardant Health Reports First Quarter 2023 Financial Results Q1 revenue increased 34% year over year driven by clinical volume growth of 45% Raises 2023 revenue guidance to $535 to $545 million PALO ALTO, Calif.
May 9, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (
May 9, 2023	10-Q	Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
May 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (
May 8, 2023	EX-99.1	Guardant Health Announces Additions to Leadership Team • Ines Dahne-Steuber named as chief operating officer • Darya Chudova promoted to chief technology officer EX-99.1 Exhibit 99.1 Guardant Health Announces Additions to Leadership Team • Ines Dahne-Steuber named as chief operating officer • Darya Chudova promoted to chief technology officer PALO ALTO, Calif. – May 8, 2023 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its leadership team with the addition of Ines Dahne-Steuber as chief operati
May 8, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (
April 27, 2023	ARS	ARS Annual ReportGROSS PROFIT (in millions) 523% GROSS REVENUE (in millions) 395% Comparison of Five-Year Cumulative Total Return GH IXIC NBI $91M 2018 2022 $47M $293M $450MUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
April 27, 2023	DEF 14A	Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( as permitted b
April 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 10, 2023	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
April 10, 2023	EX-16.1	Letter of Ernst & Young LLP, dated April 10, 2023 1
March 13, 2023	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization
March 10, 2023	SC 13G/A	GH / Guardant Health Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.3 GUARDANT HEALTH INC COMMON STOCK Cusip #40131M109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #40131M109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 8,864,071 Item 6: 0 Item 7: 8,933,365 Item 8: 0 Item 9: 8,933,365 Item 11: 8.
March 2, 2023	S-8	As filed with the Securities and Exchange Commission on March 2, 2023 S-8 As filed with the Securities and Exchange Commission on March 2, 2023 Registration No.
March 2, 2023	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Guardant Health, Inc.
February 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2023 GUARDANT HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
February 27, 2023	EX-99.1	Musa Tariq joins Guardant Health board of directors EX-99.1 Exhibit 99.1 PRESS RELEASE Musa Tariq joins Guardant Health board of directors PALO ALTO, Calif., February 27, 2023 — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world’s leading fundraising platform, Tariq is a dis
February 23, 2023	EX-21.1	List of Subsidiaries Exhibit 21.1 Subsidiaries of Guardant Health, Inc. Name Jurisdiction of Incorporation Guardant Health AMEA, Inc. Delaware Guardant Health Pte. Ltd. Singapore Guardant Health Japan Corp. Japan Guardant Holdings (Switzerland) GmbH Switzerland Bellwether Bio, Inc. Washington Morpheus Merger Sub, Inc. Delaware Guardant Health Screening Corp. Delaware Guardant Health International, Inc. Delaware Guarda
February 23, 2023	EX-99.1	Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook Q4 clinical and biopharma volumes up 41% and 24% year over year Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook Q4 clinical and biopharma volumes up 41% and 24% year over year PALO ALTO, Calif.
February 23, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
February 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 GUARDANT HEALTH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
February 14, 2023	SC 13G/A	GH / Guardant Health Inc / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 brhc10047902sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) Guardant Health, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (
February 13, 2023	SC 13G	GH / Guardant Health Inc / Capital International Investors - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
February 13, 2023	SC 13G/A	GH / Guardant Health Inc / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
February 9, 2023	SC 13G/A	GH / Guardant Health Inc / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 GUARDANT HEALTH INC COMMON STOCK Cusip #40131M109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #40131M109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 15,319,976 Item 6: 0 Item 7: 15,372,717 Item 8: 0 Item
February 9, 2023	SC 13G/A	GH / Guardant Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01022-guardanthealthinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Guardant Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 40131M109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to desig
February 3, 2023	SC 13G	GH / Guardant Health Inc / BlackRock Inc. Passive Investment us40131m1099020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) GUARDANT HEALTH, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 40131M109 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
January 9, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizatio
January 9, 2023	EX-99.1	Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results Full year clinical and biopharma volumes up 42% and 40% year over year EX-99.1 2 gh-192023xexhibit991.htm EX-99.1 Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results Full year clinical and biopharma volumes up 42% and 40% year over year PALO ALTO, Calif. January 9, 2023 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets a
December 15, 2022	EX-99.1	1 Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer •The test demonstrated 83% sensitivity for the detection of colorectal cancer with specificity of 90% •Results pave the way for first potential FDA-approved and Medicare-reimbursed blood test for colorectal cancer screening •The company will host a webcast and conference call to discuss the results today at 5:00 p.
December 15, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
December 9, 2022	SC 13G/A	GH / Guardant Health Inc / MORGAN STANLEY - MS AMENDMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Guardant Health, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 40131M109 - (CUSIP Number) November 30, 2022 - (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
November 3, 2022	EX-99.1	Guardant Health Reports Third Quarter 2022 Financial Results Q3 clinical and biopharma volumes up 42% and 40% year over year Guardant Health Reports Third Quarter 2022 Financial Results Q3 clinical and biopharma volumes up 42% and 40% year over year PALO ALTO, Calif.
November 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
August 4, 2022	EX-99.1	Guardant Health Reports Second Quarter 2022 Financial Results Q2 clinical and biopharma volumes up 40% and 65% year over year Guardant Health Reports Second Quarter 2022 Financial Results Q2 clinical and biopharma volumes up 40% and 65% year over year PALO ALTO, Calif.
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
July 7, 2022	EX-99.1	Steve E. Krognes Joins Guardant Health Board of Directors Exhibit 99.1 Steve E. Krognes Joins Guardant Health Board of Directors PALO ALTO, Calif. July 7, 2022 ? Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Steve E. Krognes to its board of directors. Mr. Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at Denali Ther
July 7, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
June 21, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
June 13, 2022	EX-99.1	Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture Exhibit 99.1 PRESS RELEASE Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture PALO ALTO, Calif. June 13, 2022 ? Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc. held by SoftBank and its affiliates, giving the company full control over operations throughout the Asia, Mi
June 13, 2022	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
June 8, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
May 6, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (
May 5, 2022	EX-99.1	Guardant Health Reports First Quarter 2022 Financial Results Q1 clinical and biopharma volumes up 47% and 45% year over year Guardant Health Reports First Quarter 2022 Financial Results Q1 clinical and biopharma volumes up 47% and 45% year over year PALO ALTO, Calif.
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
April 28, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 d345708ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of
April 28, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 9, 2022	SC 13G/A	GH / Guardant Health Inc / BlackRock Inc. Passive Investment us40131m1099030922.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) GUARDANT HEALTH, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 40131M109 - (CUSIP Number) February 28, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
February 28, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
February 28, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Guardant Health, Inc.
February 28, 2022	S-8	As filed with the Securities and Exchange Commission on February 28, 2022 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No.
February 24, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
February 24, 2022	EX-21.1	List of Subsidiaries Exhibit 21.1 Subsidiaries of Guardant Health, Inc. Name Jurisdiction of Incorporation Guardant Health AMEA, Inc. Delaware Guardant Health Pte. Ltd. Singapore Guardant Health Japan Corp. Japan Guardant Holdings (Switzerland) GmbH Switzerland Bellwether Bio, Inc. Washington
February 23, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2022 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
February 23, 2022	EX-99.1	Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook Q4 clinical and biopharma volumes up 48% and 36% year over year Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook Q4 clinical and biopharma volumes up 48% and 36% year over year REDWOOD CITY, Calif.
February 11, 2022	SC 13G	GH / Guardant Health Inc / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc
February 10, 2022	SC 13G	GH / Guardant Health Inc / MORGAN STANLEY - MS INITIAL Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Guardant Health, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 40131M109 - (CUSIP Number) December 31, 2021 - (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 10, 2022	SC 13G/A	GH / Guardant Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Guardant Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 40131M109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
February 10, 2022	SC 13G/A	GH / Guardant Health Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 1 GUARDANT HEALTH INC COMMON STOCK Cusip #40131M109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #40131M109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,801,291 Item 6: 0 Item 7: 10,758,882 Item 8: 0 Item 9: 10,758,882 Item 11:
February 9, 2022	SC 13G	GH / Guardant Health Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 0 GUARDANT HEALTH INC COMMON STOCK Cusip #40131M109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #40131M109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 800,850 Item 6: 0 Item 7: 7,566,108 Item 8: 0 Item 9: 7,566,108 Item 11: 7.4
February 8, 2022	CT ORDER	CT ORDER
February 3, 2022	SC 13G/A	GH / Guardant Health Inc / BlackRock Inc. Passive Investment us40131m1099020322.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) GUARDANT HEALTH, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 40131M109 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
January 18, 2022	SC 13G	GH / Guardant Health Inc / VIKING GLOBAL INVESTORS LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Guardant Health, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 40131M109 (CUSIP Number) January
January 7, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizat
January 7, 2022	EX-99.1	Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation Exhibit 99.1 Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation REDWOOD CITY, Calif. January 7, 2022 ? Guardant Health, Inc. (Nasdaq: GH) today announced that it has reached an agreement to settle all pending litigation concerning the company?s digital sequencing technology patents with Foundation Medicine, Inc. Pursuant to the settlement agreement
November 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
November 4, 2021	EX-99.1	Guardant Health Reports Third Quarter 2021 Financial Results Achieved record revenue of $94.8 million Growth of 35% and 58% year over year in clinical and biopharma volumes, respectively Guardant Health Reports Third Quarter 2021 Financial Results Achieved record revenue of $94.
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
October 20, 2021	EX-99.1	Guardant Health Appoints Myrtle Potter to its Board of Directors Exhibit 99.1 PRESS RELEASE Guardant Health Appoints Myrtle Potter to its Board of Directors REDWOOD CITY, Calif.? October 20, 2021 (BUSINESS WIRE) ? Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors. ?We are very pleased to welcome Myrtle Potter to our Board of Directors as we continue to build and deliver on ou
October 20, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 15, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organizati
August 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization
August 5, 2021	EX-99.1	Guardant Health Reports Second Quarter 2021 Financial Results Achieved revenue of $92.1 million, driven by 52% year over year growth in clinical volume Guardant Health Reports Second Quarter 2021 Financial Results Achieved revenue of $92.
August 5, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2021 (August 4, 2021) GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporatio
August 5, 2021	EX-99.1	Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors Exhibit 99.1 PRESS RELEASE Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors REDWOOD CITY, Calif.? August 5, 2021 (BUSINESS WIRE) ? Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced a new leadership structure to support the Company?s strategic objectives for future growth. Under this stru
June 29, 2021	SC 13D/A	GH / Guardant Health Inc / SOFTBANK VISION FUND (AIV M1) L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) SB Investment Advisers (UK) Limited 69 Grosvenor St Mayfair, London W1K 3JP Attn: Brian Wheeler (Name, Address and Telephone Number of Person Auth
June 21, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
May 17, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization)
May 6, 2021	EX-99.1	Guardant Health Reports First Quarter 2021 Financial Results Achieved revenue of $78.7 million, driven by approximately 18,400 clinical tests Guardant Health Reports First Quarter 2021 Financial Results Achieved revenue of $78.
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2021 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (
May 6, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 GUARDANT HEALTH, INC.
April 29, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) SB Inv SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Guardant Health, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40131M109 (CUSIP Number) SB Investment Advisers (UK) Limited 69 Grosvenor St Mayfair, London W1K 3JP Attn: Brian Wheeler (Name, Address and Telephone Number of Pe
April 29, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 29, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 1, 2021	S-8	File No. 333-253733 As filed with the Securities and Exchange Commission on March 1, 2021 Registration No.
February 25, 2021	EX-21.1	List of Subsidiaries Exhibit 21.1 Subsidiaries of Guardant Health, Inc. Name Jurisdiction of Incorporation Guardant Health AMEA, Inc. Delaware Guardant Health Pte. Ltd. Singapore Guardant Health Japan Corp. Japan Guardant Holdings (Switzerland) GmbH Switzerland Bellwether Bio, Inc. Washington
February 25, 2021	EX-10.19	Amendment #5 to Supply Agreement, dated January 1, 2021, by and between the Registrant and Illumina, Inc. EXHIBIT 10.19 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. AMENDMENT #5 TO SUPPLY AGREEMENT Illumina, Inc., a Delaware corporation having a place of business at 5200 Illumina Way, San Diego, CA 92122 ("Illumina") and Guardant Health, Inc.,

IT:1GH	112,00 €
DE:5GH	113,92 €

GH / Guardant Health, Inc. - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Grundlæggende statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings